Novel regulatory logic in the antibiotic resistance response of *Enterococcus faecalis* against cell envelope targeting antibiotics

Sali M. Morris[1], Georg Fritz[2], Tim Rogers[3], Susanne Gebhard[1*]

[1]Life Sciences Department, Milner Centre for Evolution, University of Bath, Claverton Down, Bath, BA2 7AY, United Kingdom; [2]School of Molecular Sciences, The University of Western Australia, WA 6009 Crawley, Australia; [3]Department of Mathematical Sciences, University of Bath, Claverton Down, Bath, BA2 7AY, United Kingdom

*Corresponding author. Phone: +44 1225 386421; E-mail: s.gebhard@bath.ac.uk;

Running title: Antibiotic resistance control in *E. faecalis*

Summary

Enterococcal infections frequently show high levels of antibiotic resistance, including to cell envelope-acting antibiotics like daptomycin (DAP). While we have a good understanding of the resistance mechanisms, less is known about the control of such resistance genes in enterococci. Previous work unveiled a bacitracin resistance network, comprised of the sensory ABC transporter SapAB, the two-component system (TCS) SapRS and the resistance ABC transporter RapAB. Interestingly, components of this system have recently been implicated in DAP resistance, a role usually regulated by the TCS LiaFSR. We here explored the interplay between these two regulatory pathways. Our results show the regulation by SapR of an additional resistance operon, *dltXABCD,* and show that LiaFSR regulates the expression of *sapRS*, placing SapRS target genes under dual control: *dltXABCD* expression depends on both antibiotic-induced cellular damage (LiaFSR) *and* the presence of a substrate drug for the sensory transporter (SapAB). We further show that this network protects *E. faecalis* from antimicrobials produced by potential competitor bacteria, providing a potential rationale for the evolution of this regulatory strategy. The network structure described here can explain why clinical DAP resistance often emerges via mutations in regulatory components, which may ultimately lead to the discovery of new therapeutic targets.

Keywords: antimicrobial peptides, cell envelope stress, antimicrobial resistance, two-component system, signalling

Introduction

The rise of antibiotic resistant bacteria is one of the greatest current threats to public health, resulting in 670,000 infections a year and 33,000 deaths in Europe alone[1]. Of these infections, the "ESKAPE" organisms[2] (*Enterococci* spp., *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacter* spp.) have driven the rising number of nosocomial and antibiotic-resistant infections in the past decade. Of these bacteria, the enterococci are the second most common causative agent of nosocomial infections in the US; including bacteraemia, endocarditis and urinary tract infections[3–5]. The two species most frequently isolated, *Enterococcus faecalis* and *Enterococcus faecium*, remain a major infection-control challenge, particularly in healthcare settings.

Enterococci became recognised as important nosocomial pathogens due to their high level of intrinsic resistance to several antimicrobials[6] (e.g. penicillin, ampicillin and cephalosporins) and their capacity to acquire further resistance determinants. One such acquired resistance is to the glycopeptide antibiotic vancomycin, which occurs through plasmid acquisition and was first reported in the 1988[7,8], 30 years after vancomycin was introduced for clinical use[9]. Despite the molecular mechanisms of vancomycin resistance in enterococci being well understood today[10], infections by vancomycin resistant enterococci (VRE) still result in serious health and economic impacts[11] and are an increasing problem worldwide.

One of the last-resort antibiotics used to treat these VRE infections is the lipopeptide antibiotic daptomycin (DAP)[12]. Disappointingly, within 2 years of clinical introduction of the drug in 2003, DAP-resistant enterococcal isolates were reported[13], and in contrast to vancomycin resistance, this occurred through a subtle chromosomal change based on the mutations in genes *liaF*, *cls* and *gdpD*[14–17]. LiaF is a transmembrane protein involved in monitoring the integrity of the cell envelope and responding to damage[18], whereas Cls (cardiolipin synthase) and GdpD (glycerol-phosphodiester phosphodiesterase) are both involved in phospholipid metabolism[14]. Of these, mutation of *liaF* has been proposed to be the first pivotal event towards daptomycin resistance[15,19]. However, the exact role of the *liaF* mutations in DAP resistance so far remains unclear.

67   LiaF is part of a three-component regulatory system, LiaFSR, which is important amongst the

68   Firmicutes for coordinating the cell envelope stress response (CESR) against antimicrobial-induced

69   damage[20–23]. The system is comprised of LiaF and a conventional two-component system (TCS): the

70   sensor kinase LiaS and the response regulator LiaR[20,24,25]. LiaF is an inhibitor of LiaS, maintaining the

71   sensor kinase in an inactive conformation[20]. Rather than detecting a specific antimicrobial compound,

72   LiaFSR responds to cell envelope damage, although the exact stimulus is unknown[26]. Upon sensing this

73   damage, LiaF releases LiaS, which is then able to phosphorylate LiaR to induce the expression of the

74   system's target operon, *liaXYZ*[19,27]. The *liaXYZ* cluster is involved in sensing and binding antimicrobials

75   at the cell surface to provide resistance[27].

76   To add to this complexity, the Lia system does not exist in isolation, but is just one of many TCSs

77   involved in monitoring cell envelope integrity, each responding to their own individual stimuli and

78   activating a unique set of target genes. The CroRS system, unique to the enterococci, is the main

79   regulator required for cephalosporin resistance[28], whereas the VicKR (YycFG) system is essential

80   across the low-CG Gram positives and is involved in regulating cell division, lipid biosynthesis, biofilm

81   and virulence[29]. An additional element of the network is the serine/threonine kinase IreK and the

82   phosphatase IreP, involved in maintaining cell wall integrity by potentially regulating peptidoglycan

83   biosynthesis and metabolism[30–32].

84   A further TCS involved in monitoring the cell envelope is EF0926/27, which we have now renamed

85   SapRS (Sensor of Antimicrobial Peptides), identified in our previous work[33]. SapRS is part of a

86   bacitracin resistance network comprised of the histidine kinase SapS, the response regulator SapR and

87   the Bce-like ABC transporters: SapAB (EF2752/51) and RapAB (Resistance against Antimicrobial

88   Peptides) (EF2050/49)[33]. The use of the sensory transporter SapAB to control the activity of SapRS

89   implements a 'flux-sensing' mechanism to regulate bacitracin resistance, as was shown for the

90   homologous system in *Bacillus subtilis*[34]. In brief, upon exposure, bacitracin binds to its membrane-

91   associated target molecule, undecaprenol-pyrophosphate (UPP), blocking the dephosphorylation and

92   recycling of UPP in the lipid II cycle of cell wall biosynthesis[35,36]. The sensory ABC transporter SapAB,

93   based on biochemical evidence from the *B. subtilis* system, forms a sensory complex with SapRS[37]. In

4

94   the absence of bacitracin, the transporter maintains the histidine kinase, SapS, in an 'OFF' state[38]. Upon

95   detection of bacitracin-UPP (BAC-UPP) complexes, SapAB switches its role from repressor to activator

96   of SapS, resulting in kinase autophosphorylation[38]. SapS can then phosphorylate SapR, which in turn

97   induces the production of the resistance transporter RapAB. RapAB, again based on evidence from its

98   *B. subtilis* homologue, frees UPP from the inhibitory grip of bacitracin using a target protection

99   mechanism[39], allowing dephosphorylation of UPP and continuation of cell wall synthesis, rendering the

100   cell resistant to bacitracin. The equivalent system in *B. subtilis* is a self-contained module, involving

101   only a single transporter (BceAB) and TCS (BceRS)[40] with no known further genes involved in its

102   signalling or resistance mechanism. However, in *E. faecalis*, we observed that the TCS SapRS is itself

103   transcriptionally induced by bacitracin, however we had not identified the regulatory system that

104   controls this expression[33].

105   Interestingly, recent work by the Arias lab demonstrated that when experimentally evolving *E. faecalis*

106   for DAP resistance in a Δ*liaFSR* background, mutations were observed in the sensory transporter

107   SapAB[41,42], suggesting a functional link between the Sap and Lia systems. In *B. subtilis*, the Lia system

108   is known to be one of the main components of bacitracin resistance[43,44], but there is currently no

109   evidence for a role of LiaFSR in response to bacitracin in *E. faecalis*. Neither is there any indication of

110   a role for the Sap system in responding to DAP exposure. However, this recent evidence suggested an

111   interplay between both the Sap and Lia systems and that, potentially, both systems may be contributing

112   to resistance against bacitracin and daptomycin.

113   In accordance with the need to deepen our knowledge of the CESR in *E. faecalis,* in this study we

114   sought to examine the potential interplay between the Sap and Lia systems and investigate the

115   involvement of further genes associated with this regulatory network. Utilising mutagenesis and

116   analysis of promoter activity, we provide evidence of the activation of LiaFSR signalling in response

117   to bacitracin and describe a direct functional link between the Lia and Sap systems by demonstrating

118   the regulation of *sapR* by LiaR in response to antibiotic exposure. We also show the contribution of an

119   additional resistance operon involved in response to bacitracin and unravel a differential response of

120   the network between bacitracin and daptomycin treatment. Our data show that interplay between SapRS

5

121 and LiaFSR signalling effectively implements a logic 'AND' gate, whereby expression of SapR target

122 genes is under dual control and requires two separate signalling inputs. These observations also explain

123 the occurrence of mutations in both regulatory systems during clinical and experimental emergence of

124 DAP resistance in enterococci found previously, thus providing a compelling model for the complex

125 CESR network in *E. faecalis*.

126

Results

128 **LiaFSR controls expression of SapRS.** As mentioned above, from previous work we had identified

129 increased expression of *sapRS* under exposure to bacitracin or mersacidin[33]. Interestingly, we also

130 showed that *sapRS* was not autoregulated, in contrast to other two component systems such as CroRS

131 and LiaFSR[20,28], and regulation did not depend on either SapAB or RapAB[33]. We therefore here first

132 aimed to identify the regulator of *sapRS*. For possible candidates, we considered potential regulators

133 that are common amongst the Firmicutes and are known to respond to bacitracin. A potential candidate

134 was LiaFSR, deemed the 'master regulator' of the CESR in *Bacillus subtilis*[43] and recently shown to

135 have a possible functional link to the Sap system[41,42]. Because of this evidence, we first aimed to

136 examine the relationship between these two systems.

137 Firstly, we had to test if LiaFSR was able to respond to bacitracin treatment. It is well established that

138 *liaX* is under the control of LiaFSR[27], and therefore we exposed *E. faecalis* harbouring a P_{liaX}-*lacZ*

139 transcriptional fusion to increasing levels of bacitracin, as a readout for LiaFSR activity. The results

140 showed a ~10-fold increase in *liaX* expression at 32 μg ml^{-1} bacitracin compared with untreated cells

141 (Fig. 1A, black line), indicating that LiaFSR can indeed respond to bacitracin exposure in *E. faecalis*.

6

Figure 1. The LiaFSR operon responds to bacitracin exposure and induces the expression of both *liaXYZ* and *sapRS,* with the absence of *sapRS* resulting in the hypersensitivity of the *liaXYZ* promoter. Cells of *E. faecalis* JH2-2 wild-type or isogenic deletion strains harbouring a P$_{liaX}$-*lacZ* (panel A) or P$_{sapRS}$-*lacZ* (panel B) transcriptional fusion were grown to exponential phase and challenged with increasing concentrations of bacitracin. β-galactosidase activity, expressed as Miller units (MU), was assayed following 1h incubation. Results are means and standard deviations for three biological repeats. The significance of induction relative to untreated cells was calculated for each strain by a one-tailed, pairwise *t*-test analysis. Significance is indicated by a filled symbol ($p < 0.05$); unfilled symbols represent no significant increases compared to uninduced conditions.

Following this, we tested if LiaR can regulate the expression of *sapRS*. To do this, we monitored the response of a transcriptional P$_{sapRS}$-*lacZ* fusion to increasing bacitracin. The results showed that in wild-type *E. faecalis* carrying the transcriptional *sapRS-lacZ* fusion, bacitracin concentrations of 16 μg ml^{-1} or higher led to significant induction of the reporter, with a three-fold increase compared to uninduced cells at 32 μg ml^{-1} (Fig. 1B, black line). Deletion of *liaR* in the reporter strain resulted in a complete loss of *sapRS* induction, with expression remaining at basal levels. This indicated that LiaR indeed regulates the expression of *sapRS* in response to bacitracin exposure, presenting first evidence of a direct functional link between the Lia and Sap regulatory systems.

A surprising feature of this LiaR regulation was the high concentration required to induce a response, as *liaX* expression only significantly increased at 32 μg ml^{-1}. One possible explanation for this might be that the response was masked by other components of the bacitracin stress response in *E. faecalis*, for example RapAB, which plays an active role in the removal of bacitracin from UPP[33], protecting the

7

156 cell from damage. In *B. subtilis*, it was observed that the RapAB equivalent, BceAB, was the primary

157 response to protect the cell from bacitracin exposure and masked the response of the Lia system[45]. To

158 prevent the induction of the main bacitracin resistance genes of *E. faecalis*, controlled by SapRS[33] and

159 thus remove potential interference with Lia signalling, we therefore introduced the P_{liaX}-*lacZ*

160 transcriptional fusion into the Δ*sapRS* background. Compared to the wild type, the expression of the

161 *liaX* promoter in response to bacitracin challenge of the deletion strain showed increased sensitivity*,*

162 significantly inducing expression from 4 µg ml^{-1} bacitracin and reaching overall higher activities (Fig.

163 1A, blue line). This showed that the weak response of Lia signalling to bacitracin in the wild type was

164 indeed due to masking effects of the resistance genes controlled by SapRS, implying the presence of

165 multiple layers of protection, similar to those observed in *B. subtilis*[45], as well as physiological links

166 between the SapRS- and LiaFSR-dependent components of the CESR in *E. faecalis*.

167 **SapRS controls the expression of the *dltABCD* operon.** To expand our understanding of the Lia/Sap

168 regulatory network, we next considered if other genes may also be under its control. Currently, the only

169 known gene under SapRS regulation is the resistance ABC-transporter operon *rapAB* [33]. In *B. subtilis*,

170 both the Lia and Bce systems act as self-contained modules, controlling the regulation of only a single

171 resistance operon each, *liaIH* and *bceAB* respectively, each encoded adjacently to its regulatory operon

172 on the chromosome [24,40,43]. However, the regulatory setup in *E. faecalis* seems to be much more

173 complex. This is supported by evidence from the literature, with the indication that the Lia system has

174 a larger operon than just itself and *liaXYZ* [27]. There is also a proposal that Lia contributes to DAP

175 resistance through the regulation of *dltXABCD* (*dlt*), although there is no evidence to date that Lia is a

176 direct regulator of this operon. Dlt is responsible for the D-alanylation of teichoic acids (TA) on the

177 bacterial cell surface, resulting in a decrease in the negative charge of the cell envelope[46], a mechanism

178 commonly involved in DAP resistance amongst the low-CG bacteria[47].

179 Interestingly, recent evidence has suggested a regulatory link between SapRS and *dlt*. When evolving

180 *E. faecium* for DAP resistance in the absence of LiaFSR, mutations occurred in the *sapAB* homologue,

181 *ycvRS*. These mutations correlated with an increase in *dlt* transcription when measured by qPCR and

182 resulted in an increase in cell surface charge[41,42]. In addition, the *dltABCD* operon is located directly

183   downstream from *sapAB* on the chromosome, suggesting a possible functional link between the genes.

184   Moreover, the promoter region of *dlt* contains a putative SapR binding site, similar to that of the *rapAB*

185   promoter (Fig. 2). This body of evidence therefore led us to investigate the contribution of LiaFSR and

186   SapRS to *dlt* regulation.

187

188

Figure 2. Schematic of the promoter regions of both *rapAB* and *dltABCD*. The sequence 150 base pairs upstream of the ATG start codons are shown. The proposed binding site for SapR on both the *rapAB* and *dltABCD* promoters is in bold and capitalised, and the likely -10 and -35 elements are underlined. The experimentally confirmed transcriptional start sites are capitalised and underlined (+1) and the translational start site is shown in italicised capitals[33,84].

189

190   To this end, we first constructed a transcriptional P$_{dltX}$-*lacZ* fusion to test *dlt* induction by bacitracin.

191   The results showed that in wild-type JH2-2 carrying the fusion, increasing bacitracin concentrations led

192   to a dose-dependent increase in *dlt* expression, resulting in ~4-fold higher activity at 32 μg ml^{-1}

193   compared to untreated conditions (Fig. 3A, black line), showing that *dlt* expression is indeed induced

194   in response to bacitracin in *E. faecalis*. When we tested the response of the reporter in strains carrying

195   deletions of either *sapRS* or *sapAB,* the results showed a decrease in basal activity in both strains and a

196   complete loss of the promoter's bacitracin response in Δ*sapR* (Fig. 3A, blue and magenta lines). Loss

197   of SapAB still resulted in induction compared with uninduced cells, but overall activities were

198   considerably lower than in the wild-type strain. This indicated that SapRS was essential for *dlt*

199   expression in response to bacitracin, but a residual amount of *dlt* induction remained in the *sapAB*

200   deletion. This is consistent with the less direct role of SapAB in signalling, i.e. via controlling SapRS

201   activity and not the target genes directly. The residual bacitracin response observed in the *sapAB* deleted

202   strain can likely be explained by increased production of SapRS due to LiaFSR signalling, which would

203   be expected to lead to increased basal activity of SapRS and thus the *dlt* promoter.

Figure 3. Induction of the resistance operon *dltXABCD* by bacitracin. Panel A indicates the experimental induction of *dltX*. Cells of *E. faecalis* harbouring a *PdltX-lacZ* transcriptional fusion were grown to exponential phase and challenged with increasing concentrations of bacitracin. Beta-galactosidase activity, expressed as Miller units (MU), was assayed following 1h incubation in wild type (WT) and deletion strain backgrounds. Results are means and standard deviations for three biological repeats The significance of induction relative to untreated cells was calculated for each strain by a one-tailed, pairwise *t*-test analysis. Significance is indicated by a filled symbol ($p < 0.05$), unfilled symbols represent no significant increases compared to uninduced conditions. Panel B indicates the mathematical model of *dltX* induction in the *E. faecalis* strains indicated in panel A.

206   As we had shown above that LiaR regulates *sapRS* expression, we next aimed to find out if deletion of

207   *liaR* also influenced *dlt* expression. When we tested the response of the *dltX* promoter fusion to

208   bacitracin in a strain carrying deletion of *liaR*, we observed that deletion of *liaR* resulted in a noticeably

209   weaker amplitude of *dlt* expression in response to bacitracin, being ~2-fold lower than the wild-type

210   strain at 32 μg ml^{-1} (Fig. 3A, yellow line). In addition, the sensitivity of the *dlt* promoter response was

211   much lower in the *liaR* deletion compared with the wild-type response, with significant activation over

10

212   baseline occurring at 16 μg ml^{-1} rather than at 2 μg ml^{-1} in the wild type. However, there was no effect

213   on basal activity of *dlt*, in contrast to deletion of *sapR* and *sapAB*. These data are consistent with LiaR

214   regulating *sapRS* expression, and SapRS being the actual regulator of *dlt* expression in response to

215   bacitracin.

216   As we had observed before with the *liaX* and *sapRS* promoters, we also wanted to investigate if the

217   protection provided by the SapRS-target RapAB was dampening the expression of *dlt* in response to

218   bacitracin. To examine this, we tested the response of *dlt* expression in the absence of *rapAB*. In a

219   *ΔrapAB* background, the *dlt* promoter demonstrated markedly increased sensitivity, and a much

220   stronger response to bacitracin, resulting in a ~3-fold increase in expression at 2 μg ml^{-1} when compared

221   to the wild-type (Fig. 3A, orange line). This response demonstrated the presence of a layered protection

222   with RapAB activity moderating *dlt* expression.

223   Overall, these findings were rather surprising, as the signalling pathway appeared remarkably complex

224   to result in a relatively simple outcome, i.e. inducing the expression of two resistance genes in response

225   to an antibiotic. To test if our understanding of the regulatory pathway was plausible, we therefore

226   developed a representative mathematical model to see if this would reproduce the behaviour we had

227   observed in the experiments. At the core, this model was based on a simplified form of the flux-sensing

228   mechanism described previously for the *B. subtilis* BceRS-BceAB system[34], which was then expanded

229   upon to reproduce the hypothesised network structure investigated here. In brief, the model considered

230   bacitracin binding to UPP to form UPP-bacitracin complexes with the on-rate dependent on the

231   bacitracin concentration. These complexes then drive transport activity of, in this case, SapAB,

232   according to a soft-switch type functional response (see Methods), which the model translates into

233   activation of SapRS and thus *dlt* expression. Importantly, SapRS activity also drives expression of the

234   resistance transporter operon, in this case *rapAB*, and production of RapAB leads to a reduction in

235   formation of UPP-bacitracin complexes due to the target protection activity of the transporter[34,39]. This

236   creates the negative feedback loop that is characteristic of the flux-sensing mechanism and leads to the

237   gradual response behaviour of the output promoters (Fig. 3B, black symbols). To adapt this model to

238   the Lia-Sap regulatory pathway of *E. faecalis*, we additionally considered the activity of the Lia system.

239   This was modelled to also respond to UPP-bacitracin complexes in a switch like manner representing

240   the generation of cellular damage caused by these complexes. The model then linked the Lia and Sap

241   components by modulating the SapRS signalling output (i.e. *dlt* and *rapAB* expression) according to

242   Lia activity, driven by bacitracin. The mathematical details of the model are explained in the Methods

243   section. Fitting to experimental data was performed by matching differential activity of SapRS against

244   both *rapAB* and *dlt* recorded at different bacitracin concentrations.

245   This model accurately reflected the behaviour of our experimental strains, depicting the same gradual

246   response to bacitracin of the *dltX* promoter in wild-type *E. faecalis* (Fig. 3B, black symbols), as well as

247   the hypersensitive response in the *rapAB* deletion strain, where the negative feedback from RapAB-

248   driven removal of bacitracin was missing (orange symbols). Importantly, the model gave the same

249   complete loss of *dltX* activity when *sapRS* was deleted (blue symbols) as observed experimentally, as

250   well as the normal basal level activity but loss of bacitracin-dependent induction when *liaR* was deleted

251   (yellow symbols). A *sapAB* deletion strain was not specifically considered as the model did not

252   differentiate between SapAB and SapRS activities and thus both strains would have been

253   mathematically identical. This close agreement between theoretical and experimental data strongly

254   suggested that our reconstruction of the regulatory pathway and connection between the Lia and Sap

255   systems was theoretically plausible and that no further major players were needed to explain the

256   behaviour of the *dltX* target promoter in the various mutant backgrounds analysed here.

257

258   **Daptomycin induces the expression of *sapRS* but not *dltABCD*.** We had now established a sequential

259   order of *dlt* regulatory control; in response to bacitracin, LiaFSR induces the expression of *sapRS*, and

260   in turn SapRS, activated by its sensory transporter SapAB, induces the expression of *dlt*. However,

261   treatment with bacitracin made it difficult to separate out the individual contributions to regulation by

262   LiaFSR and SapRS, as both signalling systems respond to this antibiotic. Bacitracin forms a complex

263   with UPP, which acts as the input for SapRS signalling via SapAB[39]; at the same time, bacitracin

264   induces cell envelope damage, triggering LiaFSR activation[26]. To allow us to differentiate between the

265   contribution made by each regulator to the network, we instead required an antibiotic that would only

12

266   trigger signalling by one of the systems. To this end, we turned to daptomycin (DAP), which activates

267   the Lia system by causing damage to the cell envelope[48,49]. However, it does not bind to UPP or the

268   sugar-pyrophosphate moiety of Lipid II, which is the common feature of substrates for BceAB-type

269   transporters[39]. Indeed, the tripartite complex of DAP with Lipid II and phosphatidyl glycerol in the

270   membrane[50] is unlikely to be recognised by SapAB, and thus DAP exposure should not trigger SapRS

271   activation, allowing us to study the specific impact of LiaFSR signalling in the regulatory pathway.

272

273

Figure 4. Exposure to daptomycin results in the induction of *sapRS* but does not induce the expression of *dltXABCD*. Cells of *E. faecalis* harbouring a P_{sapRS}-*lacZ* (panel A) or a P_{dltX}-*lacZ* (panel B) transcriptional fusion were grown to exponential phase and challenged with increasing concentrations of daptomycin. Beta-galactosidase activity, expressed as Miller units (MU), was assayed following 30 minutes incubation in wild type (WT) and deletion strain backgrounds indicated. Results are means and standard deviations for two biological repeats. The significance of induction relative to untreated cells was calculated for each strain by a one-tailed, pairwise *t*-test analysis. Significance is indicated by a filled symbol (P < 0.05), unfilled symbols represent no significant increases compared to uninduced conditions.

274

275   To investigate the effect of DAP exposure on LiaFSR and SapRS signalling and target gene expression,

276   we again utilised transcriptional promoter fusions. The P_{sapRS}-*lacZ* transcriptional fusion (LiaFSR

277   target) in the wild-type background showed a ~2-fold induction upon DAP treatment when compared

278   to unexposed levels (Fig. 4A). As we had seen for bacitracin-induction, deletion of *liaR* again

279   completely abolished *sapRS* activation, showing the induction of *sapRS* by DAP was occurring through

280   LiaR regulation. This showed that DAP exposure indeed triggered LiaFSR signalling.

281   To test how DAP induction was propagated further down the regulatory pathway, we next exposed the

282   P_{dltX}-*lacZ* transcriptional fusion (SapRS target) to increasing DAP concentrations. Surprisingly, in wild-

283   type *E. faecalis*, we found daptomycin treatment did not result in any induction of *dlt*, with expression

284   remaining at basal levels across all tested concentrations (Fig. 4B). As seen for the bacitracin challenge,

285   deletion of *sapRS* resulted in a decrease in basal expression, from 20 MU to 7.5 MU, and again, there

286   was no induction of the *dlt* promoter in response to daptomycin exposure. This indicated that although

287   *sapRS* transcription was induced in response to daptomycin treatment, remarkably, expression of its

288   target gene *dlt* remained at basal levels. This discovery suggested a differential response in the

289   signalling cascade dependent on the inducer, indicating that bacitracin and daptomycin might be

290   differentially sensed by SapRS, as further explained in the discussion.

291   **The network components vary in importance during interactions with antimicrobial producer**

292   **strains.** As stated above, we were surprised by the complexity of the regulatory pathway controlling

293   what in other Firmicutes bacteria is a fairly straightforward response to antibiotic challenge, where each

294   regulatory system controls its own resistance genes. To shed some light on the reasons for the

295   complexity of signalling in enterococci, we considered the environments these bacteria can be found

296   in. *E. faecalis* is a common member of many natural microbial communities, such as in soil and water

297   or the gastrointestinal tract of humans and animals. There, the enterococci reside within the small and

298   large intestine and represent up to 1% of the faecal flora[51–54]. In such environments, *E. faecalis* interacts

299   with other microbes and must defend itself against antimicrobial producing bacteria. Therefore, we next

300   wanted to assess the role of the individual components of the resistance network in protecting *E. faecalis*

301   from antimicrobial activity produced by potential competitor bacteria. To do this, we utilised deferred

302   antagonism assays to simulate relevant environmental pressures from other microbes the enterococci

303   may encounter. We used four antimicrobial producing strains: the subtilin producer *Bacillus subtilis*

304   ATCC6633[55], bacitracin producer *Bacillus lichenformis* ATCC10716[56], nisin-A producer *Lactococcus*

305   *lactis* NZ9000[57] and nisin-P producer *Streptococcus gallolyticus* AB39[58]. Each producer was spotted

306   onto a plate, and the antimicrobial was allowed to accumulate over multiple days. This was followed

307   by the addition of an overlay containing the different *E. faecalis* strains to assess their sensitivity against

308   the produced compounds based on the size of the zone of inhibition (Fig. 5).

309   Firstly, we tested the *E. faecalis* strains against the antimicrobial subtilin, produced by *B. subtilis*

310   ATCC6633. Of the components under investigation in this study, the LiaFSR system appeared to

311   contribute most strongly to resistance against subtilin, as the Δ*liaR* mutant displayed the largest increase

312   in zone of inhibition compared to the wild type. The deletions of *sapR*, *sapAB* and *rapAB* also displayed

313   an increased zone of inhibition compared to the wild type, but to a lesser extent than Δ*liaR*. This

314   therefore suggests they play a lesser role in subtilin resistance.

315   In contrast, when testing the *E. faecalis* strains against the bacitracin producer *B. lichenformis*

316   ATCC10716, deletion of *sapR, sapAB* and *rapAB* showed similar increased sensitivity, consistent with

317   their contribution to the bacitracin resistance network that we have examined in this study and

318   previously[33]. Although also presenting increased sensitivity compared with the wild type, deletion of

319   *liaR* resulted in a marginally smaller zone of inhibition compared with the other deletion strains. This

320   is in line with our data presented above, showing the Lia system has a more indirect role in controlling

321   the bacitracin response by regulating *sapRS* expression.

322

323

Figure 5. *E. faecalis* **deletion strains show differential zones of inhibition in deferred antagonism tests against antimicrobials produced by other firmicute bacteria.** The antimicrobial producer strains indicated at the top were grown overnight and then adjusted to an OD_{600} of 0.5 with fresh media. Aliquots (5ul) from each producer strain was then spotted and incubated at 25°C for 36-45 hours to allow antimicrobial accumulation. Overnight cultures of the *E. faecalis* strain indicated on the left were then added as a soft agar overlay. Plates were incubated at 25°C for 24 hours and zones of inhibition in the *E. faecalis* lawn were used to assess susceptibility to antimicrobials produced by the central strain.

We next tested the *E. faecalis* mutants against the nisin producers, *L. lactis* NZ9000 and *S. gallolyticus* AB39. Although there was some inhibition of wild type *E. faecalis* by the nisin-A producer *L. lactis*, there was no difference in sensitivity between the wild type and deletion strains. This suggests either that the genes of our regulatory pathway do not contribute to resistance against this antibiotic, or that

16

330   under the chosen conditions the inhibitory activity of *L. lactis* NZ9000 is primarily due to a different

331   antimicrobial than nisin-A. In contrast, the nisin-P producer *S. gallolyticus AB39*, despite having no

332   inhibitory effect on wild type *E. faecalis*, was able to strongly inhibit growth of the *liaR* deletion strain.

333   Deletions of both *sapR* and *sapAB* also resulted in increased sensitivity but to a lesser degree than *liaR*

334   deletion. Deletion of *rapAB* had little to no effect compared to the wild type, suggesting that the other

335   target genes of the regulatory pathway but not the RapAB transporter are responsible for nisin P

336   resistance.

337   These findings indicate that in response to different antimicrobials, the various members of this

338   resistance network have differing roles to play and also differ in their relative importance. In response

339   to subtilin and nisin-P, LiaR clearly plays a very important role in resistance, but it is a less important

340   component in response to bacitracin exposure. This reflects LiaR's role as a key regulator in the cell

341   envelope stress response more widely, but with mostly a moderating role in response to bacitracin. The

342   *sapR*, *sapAB* and *rapAB* deletions all present with very similar effects in response to the antimicrobials,

343   reflecting the interdependent functional relationship between the three components. The notable

344   exception to this is RapAB in the context of nisin-P, where the transporter does not appear to contribute

345   to protection of the cell.

346

Discussion

348   In this study, we aimed to expand our understanding of the cell envelope stress response of *E. faecalis*

349   using the previously described bacitracin resistance network as our foundation. Our findings revealed

350   the regulation of the BceRS-type TCS SapRS via the damage sensor, LiaFSR. In addition, we also

351   demonstrated the regulation of the resistance operon *dltXABCD* via SapRS. This work describes a direct

352   functional link between the Lia and Sap signalling systems in *E. faecalis*, which can explain previous

353   observations of suppressor mutations in *sapAB* when a LiaR-deficient strain was evolved for DAP

354   resistance[41,42]. Moreover, through creation of deletion strains and analysing promoter fusions, we have

355   revealed the presence of a differential network response through the damage-sensing LiaFSR and drug-

356   sensing SapAB-SapRS systems, leading to *dlt* expression in response to bacitracin, but not daptomycin.

357   This discovery implies there is distinct control on subsections of the network depending on the inducer.

358   To understand the mechanisms of this differential control, the mode-of-actions of both antibiotics must

359   be considered. Bacitracin is a peptide antibiotic, which forms a complex with undecaprenyl

360   pyrophosphate (UPP), an intermediate of the Lipid II cycle[35,36]. The formation of this complex prevents

361   the dephosphorylation of UPP and slows cell wall formation[59,60]. In contrast, daptomycin is a

362   lipopeptide antibiotic which forms a tripartite complex between lipid II and the membrane phospholipid

363   phosphatidyl glycerol[50]. The formation of this complex leads to a loss of membrane potential and cell

364   death. The similarity between both antibiotics is the formation of cell envelope damage, the known

365   stimulus for the activation of the "damage sensor" LiaFSR. However, they differ in their mechanism of

366   action with bacitracin preventing cell wall synthesis and daptomycin directly affecting cell membrane

367   integrity.

368   Since both antibiotics cause cell envelope damage, both lead to induction of LiaR target genes (Figures

369   1&3), including *sapRS*. SapAB, the sensory transporter that controls SapRS activity, however, so far

370   has been shown to be activated by only two antibiotics, bacitracin and mersacidin [33], both of which bind

371   to lipid II cycle intermediates[35,61,62]. This is consistent with the current working model for BceAB-type

372   transporters, to which SapAB belongs, recognising the complex between a peptide antibiotic and a lipid

373   II cycle intermediate as their substrate[39]. Importantly, the type of antibiotics to which BceAB-type

374   transporters respond all interact with the lipid II cycle intermediates via at least the pyrophosphate group

375   (e.g., bacitracin) or the sugar-pyrophosphate moiety of Lipid II (e.g. the lantibiotics, including

376   mersacidin)[62,63]. In the case of bacitracin, it is therefore the presence of bacitracin-UPP complexes that

377   triggers SapAB activity, leading to SapRS activation via the transport flux-sensing mechanism

378   demonstrated for the *B. subtilis* system[34,38]. Thus, the presence of bacitracin triggers both Lia and Sap

379   signalling simultaneously, inducing the expression of *dlt*.

380   In contrast, DAP interacts with its cellular target in a fundamentally different way, forming a tripartite

381   complex between Lipid II and phosphatidyl glycerol (PG)[50]. It therefore would not be expected to form

382   the type of complexes that could act as substrate for SapAB[39], and Sap signalling is not activated.

18

383   BceAB-type transporters have been shown to repress histidine kinase activity in the absence of

384   substrate[38]. Thus, the lack of a SapAB substrate likely leads to the transporter maintaining SapS in an

385   'OFF' conformation, preventing activation of SapR target genes, i.e. *dlt.* Such a mechanism can explain

386   why in the presence of DAP, when the LiaFSR system activates expression of the *sapRS* operon, no

387   induction of *dlt* expression was observed, because SapAB – unable to detect the tripartite DAP/lipid

388   II/PG complex - would have prevented SapRS signalling.

389   Taken together, these findings indicate the presence of a logic 'AND' gate, whereby two inputs (the

390   damage sensing input provided by LiaFSR and the drug-sensing input provided by SapAB) are needed

391   to obtain the output, which is the induction of *dlt* expression (Figure 6). This mode of regulation offers

392   an explanation for the mutations observed previously in *sapAB* when evolving for DAP resistance in

393   the absence of *liaR*[41,42]. A gain-of-function mutation in *sapAB* would allow the activation of Sap

394   signalling in the absence of a substrate and induce *dlt* expression, essentially overriding the 'AND' gate

395   and providing DAP resistance. This working model also explains the low but statistically significant

396   induction of *dlt* expression by bacitracin we observed in the absence of *sapAB* (Fig. 3). The mutant still

397   possesses SapRS and thus bacitracin-challenge leads to activation of *sapRS* expression via LiaR. This

398   in turn is likely to cause an increase in basal activity of SapRS-signalling and thus moderate *dlt*

399   activation, even if the full activation via SapAB is missing. A similar effect has been described

400   previously for the second known SapRS target, *rapAB*, where deletion of *sapAB* resulted in low

401   promoter activity of *rapAB*, but with a small level of residual bacitracin response remaining[33].

402   The regulatory wiring we have uncovered here between the LiaFSR and the Bce-type SapAB-SapRS

403   systems, resulting in the control of the *dltXABCD* and *rapAB* resistance operons, is remarkably complex

404   compared with other Firmicutes bacteria. For example, in *B. subtilis* LiaFSR controls its own regulon,

405   comprised solely of *liaIH(G)* and its own encoding genes [24]. In *S. aureus*, the LiaFSR homologue VraRS

406   has been shown to regulate the expression of multiple genes involved in cell wall biosynthesis[64], but

407   has not been observed to regulate a BceRS-type TCS. Bce-type systems in most Firmicutes bacteria

408   either solely control their own transporter, as found with BceAB-RS in *B. subtilis*[40], or can be involved

409   with other Bce-type systems, such as the BraRS-VraDE[65] and GraRS-VraFG[66] systems in *S. aureus*. In

410　　some cases, Bce-type systems can also control additional genes, for example the GraRS TCS has also

411　　been shown to regulate the *dlt* operon[67–69]. However, to our knowledge there have been no prior reports

412　　of direct regulatory relationships that hardwire the Lia and Bce-type pathways together.

413

414

Figure 6. Proposed model of the antibiotic resistance network. Schematic illustrating the genes and proteins involved in antibiotic detection and resistance, with transcriptional regulation and translation demonstrated by black and red arrows respectively. Exposure to bacitracin (BAC) causes damage to the cell envelope, which acts as the stimulus for the removal of repression by LiaF, triggering the activation of LiaS. LiaS activity leads to phosphorylation of LiaR, which in turn induces the expression of its target promoters: its own, *liaXYZ* and *sapRS*, indicated by the black arrows. Simultaneously, bacitracin is also detected by SapAB. Communication between SapAB and SapS is indicated by a faded arrow, resulting in the activation of SapS and phosphorylation of SapR. SapR then induces the expression of the resistance genes, *rapAB* and *dlt,* which remove bacitracin from UPP and reduce the positive charge of the cell envelope, respectively. Conversely, exposure to daptomycin (DAP) again results in cell envelope damage, which triggers the phosphorylation of LiaR and induces the expression of *sapRS*. However, daptomycin is not recognised by SapAB, therefore SapS is kept in an 'OFF' conformation and SapR is not phosphorylated. SapR is therefore unable to induce the expression of *rapAB* and *dlt*.

415

416　　Our findings reported here show that although the enterococci possess the same regulators as *S. aureus*

417　　and *B. subtilis*, evolution has taken these components down different routes. A potential reasoning

418　　behind *E. faecalis* maintaining this intricate setup could be that having *dlt* and *rapAB* under Sap control,

419　　and *sapRS* itself under Lia regulation, may provide the cell with a layered response. Under this premise,

420   when the cell is experiencing a mild bacitracin attack, signalling in the Lia-Sap pathway is likely to be

421   dominated by the Sap system, which responds to the presence of UPP-bacitracin complexes, even if

422   those do not yet cause cellular damage. Sap signalling then activates both *rapAB* and *dltXABCD*. Of

423   these, RapAB provides the main target protection mechanism, especially at lower antibiotic

424   concentrations, whereas expression of *dlt* is likely of minor importance, based on evidence from *B.*

425   *subtilis*[39,45]. This is consistent with our observations in *E. faecalis,* where the strength of *rapAB*

426   induction is much higher than that of *dlt*: at 4μg/mL bacitracin, *rapAB* expression reaches >100 MU [33],

427   compared to *dlt*, which reaches a maximum of 25 MU (Fig. 3). However, when the antibiotic threat

428   begins to exceed the protection level RapAB can provide, damage to the cell occurs and the Lia system

429   is activated. LiaFSR is then able to boost the signalling cascade by increasing *sapRS* expression. We

430   see this in the absence of *rapAB*, which mimics an extreme failure of target protection, leading to a

431   drastic increase in *dlt* expression (Fig. 3). Thus, the regulatory structure between Lia and Sap signalling

432   in *E. faecalis* allows a second line of defence to be mounted if the primary resistance system is no longer

433   sufficient to fully protect the cell.

434   The genes discussed here are all part of the core genome of *E. faecalis* and thus contribute to intrinsic,

435   rather than acquired drug resistance in this bacterium. To better understand the evolutionary context

436   that appears to have given rise to the unusually complex regulation of the resistance genes, we

437   considered the broader scope of this network - was it able to protect the enterococci from antimicrobial

438   challenge from potential competitors in their natural environments? The importance of the role played

439   by LiaFSR in the cell envelope stress response was well demonstrated by the antagonism assays, in

440   which deletion of *liaR* resulted in increased sensitivity against all tested antimicrobial producers, except

441   for *L. lactis* NZ9000 (nisin-A). In contrast, components of the Sap system only contributed to protection

442   from the bacitracin producer *B. lichenformis* ATCC10716 and the subtilin producer *B. subtilis*

443   ATCC6633. The only antimicrobial producer against which neither of the genes appeared to give a

444   protective effect was the nisin-A producer *L. lactis* NZ9000. However, we cannot currently differentiate

445   whether this was because *L. lactis* did not produce sufficient nisin-A under the chosen growth conditions

446   to detect differences, or because *E. faecalis* uses alternative resistance mechanisms against nisin-A not

447 controlled by either the Lia or Sap systems. Overall, it appears that the regulatory network studied here

448 plays a key role in protecting *E. faecalis* from antimicrobial peptide producing bacteria that it would

449 realistically encounter in its natural habitats, offering an explanation for the existence of such a complex

450 regulatory strategy.

451 One of our most striking results was that daptomycin challenge, although able to activate Lia signalling,

452 was unable to activate the Sap system, potential mechanistic reasons for which are explained above.

453 This was a surprising finding, as *dlt* is known to respond to daptomycin in other Firmicutes, e.g. *S.*

454 *aureus* [70–74]. The lack of *dlt* expression in response to DAP may, however, explain the sensitivity to this

455 antibiotic observed throughout the *Enterococcus* genus and its effectiveness when treating VRE

456 infections[75]. This is despite the bacteria being in possession of an effective resistance mechanism, except

457 this is not induced upon DAP challenge. It is then plausible to see why clinical DAP resistance could

458 result from overriding of the molecular controls investigated here to trigger high *dlt* operon expression,

459 specifically via mutations in genes encoding the components of the LiaFSR system[19], or experimentally

460 in *sapAB* as suppressor mutations of a LiaR-deficient strain[41,42]. DAP was introduced for treatment of

461 enterococci infections in 2003[12] and the first resistant isolates were identified already in 2005[13]. It may

462 be that the rapid emergence of DAP resistance is in part derived from a dysregulation of *dlt* expression

463 by such mutations of regulatory components.

464   Overall, our findings contribute to an increasing understanding of the regulatory network protecting *E.*

465 *faecalis* from cell envelope attack and provide insights into the regulatory cascade that is involved in

466 controlling resistance gene expression in response to cell envelope targeting antibiotics. Our findings

467 also provide valuable context in which to better understand the emergence of DAP resistance in clinical

468 environments. Ultimately, a system-wide understanding of antimicrobial resistance regulation may lead

469 to identification of an 'Achilles' heel' within the network and identify new therapeutic targets.

470

471 **Experimental Procedures**

472 **Bacterial strains and growth conditions.** All bacterial strains and plasmids used in this study are listed

473 in Table S1 in the supplementary material. *E. coli* MC1061 was used for cloning with pTCVlac, and

474 strain DH5α was used for all other cloning. *E. coli*, *Bacillus licheniformis* and *Bacillus subtilis* were

475 routinely grown in lysogeny broth (LB) at 37°C with agitation (200 rpm). *Lactococcus lactis* was grown

476 routinely in M17 supplemented with 0.5% lactose at 30°C without agitation. *Enterococcus faecalis and*

477 *Streptococcus gallolyticus were* grown routinely in brain heart infusion (BHI) at 37°C without agitation,

478 with media for the latter being supplemented with 5% (v/v) foetal bovine calf serum. Solid media

479 contained 15 g l^{-1} agar. Selective media contained chloramphenicol (10 µg ml^{-1} for *E. coli*; 15 µg ml^{-1}

480 for *E. faecalis*), kanamycin (50 µg ml^{-1} for *E. coli*; 1000 µg ml^{-1} for *E. faecalis*), spectinomycin (100

481 µg ml^{-1} for *E. coli*; 500 µg ml^{-1} for *E. faecalis*). For blue-white screening, 5-bromo-4-chloro-3-indolyl-

482 β-d-galactopyranoside (X-Gal) was used at 120 µg/ml. Bacitracin was supplied as the Zn^{2+} salt. All

483 media for experiments with daptomycin were supplemented with 50 µM $CaCl_2$.

484 *E. faecalis* was transformed by electroporation as previously described[76]. *E. coli* was transformed by

485 heat-shock of $CaCl_2$ competent cells, followed by 1 hour recovery time[77]. Growth was measured as

486 optical density at 600 nm (OD_{600}) on a the Biochrom™ Novaspec Pro Spectrophotometer using cuvettes

487 with 1 cm light path length or in 96-well plates with 100 µL culture volumes on a Spark®Microplate

488 reader (Tecan).

489 **Construction of plasmids and genetic techniques.** All primer sequences used for cloning are listed in

490 Table S2 in the supplementary material. Transcriptional promoter fusions to *lacZ* in *E. faecalis* were

491 constructed in the vector pTCVlac[78]. All fragments were cloned via the EcoRI and BamHI sites of the

492 vector. Constructs for unmarked deletions in *E. faecalis* were cloned into pLT06[79]. For each gene or

493 operon to be deleted, 700- to 1000-bp located immediately before the start codon of the first gene ("up"

494 fragment) and after the stop codon of the last gene ("down" fragment) were amplified. The primers

495 were designed to create a 17- to 20-bp overlap between the PCR products (Table S2), facilitating the

496 fusion of the fragments by PCR overlap extension[80] and were subsequently cloned into the NcoI and

497 BamHI site of the vector pLT06. Gene deletions were performed as previously described[79]. Briefly,

498 following transformation of the parent strain with the temperature-sensitive vector pLT06, overnight

23

499   cultures were grown at 30° containing chloramphenicol and reinoculated 1:1000 into 10 mL BHI the

500   next morning. Cells were then grown at 30° for 2.5 hours, followed by increasing to 42° for a further

501   2.5 hours to force single-site integration. Cells were then serially diluted onto BHI agar containing

502   chloramphenicol and X-Gal and incubated at 42°. Blue colonies growing at 42°C were screened for the

503   targeted integration using PCR with primers flanking the site of integration. Positive clones were then

504   serially passaged for two days from overnight culture in BHI medium with no selection at 30° to allow

505   a second site recombination event. Cultures were then serially diluted on to MM9-YEG agar[81]

506   containing 10 mM p-chloro-phenylalanine for counter-selection and X-Gal at 37°C. The resulting white

507   colonies were screened for the deletion of the target genes by PCR. All cloned constructs were checked

508   for PCR fidelity by Sanger sequencing, and all created strains were verified by PCR using the primers

509   given in Table S2.

510   **Antimicrobial susceptibility assays.** For antibiotic susceptibility assays, minimum inhibitory

511   concentrations (MICs) were determined by broth dilution assays in BHI medium in 96-well plates,

512   containing serial two-fold dilutions of antibiotic. Colonies of *E. faecalis* were suspended in sterile

513   Phosphate Buffered Saline (PBS) to 0.5 McFarland standard turbidity and diluted 1:1,000 in a total

514   volume of 100μL. After 24 h incubation at 37°C, growth was determined by measuring optical density

515   (OD_{600}) on a Spark®Microplate reader (Tecan). The MIC was scored as the lowest antibiotic

516   concentration where no growth was observed following subtraction of the OD_{600} of a well containing

517   sterile medium.

518   **β-Galactosidase assays.** For quantitatively assessing induction of *lacZ* reporter constructs in *E.*

519   *faecalis*, exponentially growing cells (OD_{600} = 0.4-0.5) inoculated 1:250 from overnight cultures in BHI

520   medium were exposed to different concentrations of bacitracin for 1 h or daptomycin for 30 minutes.

521   Cells were harvested via centrifugation and stored at -20°C. β-Galactosidase activities were assayed in

522   permeabilised cells and expressed in Miller units (MU)[82]. For this, cells were resuspended in 1 ml Z-

523   buffer (8.04 g $Na_2HPO_4*7H_2O$, 2.76 g $NaH_2PO_4*H_2O$, 0.123 g $MgSO_4*7H_2O$ and 5 mL 1M KCl in 495

524   mL dH_2O, pH 7). The samples were adjusted to OD_{600} = 0.5 in a 1 ml volume of Z-buffer and from this,

525   two volumes were taken: 200 μl and 400 μl cells made up to 1 mL each with Z-buffer. This volume

526 corresponds to the 'volume of cells' in the Miller Unit (MU) equation below. Following this, 20 µl

527 0.1% (w/v) SDS and 40 µl chloroform were added and vortexed for 5 seconds, then rested for 5-10

528 minutes. Reactions were started by adding 200 µl o-nitrophenyl-β-D-galactopyranoside (ONPG) (4 mg

529 mL^{-1} in Z-buffer) and incubated at room temperature until yellow colouration was observed. If no colour

530 change was visible, the reaction was incubated for 20 minutes. Reactions were stopped by adding 500

531 µl 1M Na$_2$CO$_3$, and the time recorded, which corresponds to the 'time' in the Miller Unit (MU) equation

532 below. Absorbance at 420 nm (A$_{420}$) was then read. MUs were calculated using the following equation:

533
$$Miller\ Units\ (MU) = \frac{A420 * 1000}{Time\ (minutes) * volume\ of\ cells\ (in\ ml) * OD600}$$

534 **Computational modelling.** Rather than directly modelling the temporal dynamics of the regulatory

535 network as done for the *B. subtilis* Bce system[34,83], we chose to focus on the (meta) stable state reached

536 in response to challenge with a given bacitracin concentration. The quantities modelled are the

537 concentrations of bacitracin [bac], UPP [UPP], UPP-bound bacitracin [$UPPbac$], and the effective

538 activities of SapRS [$SapRS$], RapAB [$RapAB$], LiaX [Lia], and DltXABCD [Dlt]. For the modelling,

539 we made repeated use of a soft-switch sigmoid type function

540
$$f_y(\mathrm{x}; y_{\mathrm{base}}, y_{\mathrm{max}}, \mathrm{x}_0, \mathrm{k}) = f_{\max}\left(1 + \left(\frac{y_{\max}}{y_{\mathrm{base}}} - 1\right)e^{-k(x-x_0)}\right)^{-1},$$

541 where x is the input quantity and y the output which varies between y_{base} and y_{max}, with x_0 controlling

542 the switching threshold and k setting the sharpness of the transition. The equations of state for the model

543 are then simply

544
$$k_{on}([Dlt])([bac] - [UPPbac])[UPP] - k_{off}([RapAB])[UPPbac] = 0$$

545
$$[Lia] = f_{Lia}([UPPbac])$$

546
$$[SapRS] = f_{SapRS}([Lia])$$

547
$$[Dlt] = f_{dlt}([SapRS])$$

548
$$[RapAB] = f_{RapAB}([SapRS])$$

25

549   We modelled the binding and off rates for the UPP / bacitracin interaction as being linearly proportional

550   to [*Dlt*] and [*RapAB*], respectively, with Dlt reducing bacitracin binding and RapAB increasing the off-

551   rate. The biological reasoning for this is explained in the Results section.

552   For [*bac*], actual values from the experimental work were used, and the switching parameters for [*Dlt*]

553   and [*RapAB*] as functions of [*SapRS*] were determined by fitting actual activity levels observed

554   experimentally of these quantities for different bacitracin levels. The remaining parameters were fitted

555   to achieve a description of experimental results for the wild-type strain by the model output. The values

556   for each parameter are given in Table S3. Solving the equations of state for a given input bacitracin

557   level [*bac*] yielded predictions for [*UPP*] and [*UPPbac*], which in turn drive the response curves plotted

558   in Figure 3B.

559   **Antagonism assays on solid media.** A plate-based assay was utilised to measure growth inhibition

560   between antibiotic producer strains and *E. faecalis* strains. For each species, cultures of the

561   antimicrobial-producing bacteria were grown overnight in the respective growth medium and

562   temperatures stated above and adjusted to $OD_{600} = 0.5$. Aliquots (5 µl) from each producer culture were

563   spotted onto the centre of a BHI agar plate and incubated at room temperature (20-25°C) for 3-5 days

564   to allow accumulation of antimicrobial products. Overnight cultures of *E. faecalis* strains were grown

565   at 37°C in BHI medium, inoculated 1:100 into fresh medium and grown to OD = 0.5. Next, 3 mL of

566   liquid BHI soft agar (7.5 g/L, 50°C) were inoculated with 30 µL culture. The soft agar was then poured

567   onto the plate containing the pre-grown antimicrobial-producing strains and left to dry. The plate was

568   then incubated overnight at room temperature to allow *E. faecalis* to grow to visualise the zone of

569   inhibition. Results were recorded photographically using a PowerShot G camera attached to a lightbox.

570   **Data accessibility.** The numerical data underpinning the results shown in Figures 1, 3 and 4 are

571   available in Table S4. The *Mathematica* file for the model is provided in the supplementary material.

572

573   # Acknowledgements

579

Author contributions

581   SMM, SG, TR and GF contributed to the conception of the study; SMM and SG designed the

582   experimental work; SMM carried out all data acquisition; SMM, TR and SG carried out data analysis

583   and interpretation; SMM, SG, TR and GF wrote the manuscript.

584

Graphical abstract

586

Abbreviated summary

588   This study explored a regulatory network controlling resistance against daptomycin and bacitracin in

589   *E. faecalis*. We show that the *dltXABCD* operon, which can protect against both antibiotics, is

590   controlled by two regulatory systems, LiaFSR and SapRS. Strikingly, this strategy allows *dtlXABCD*

591   expression only in response to bacitracin, but not daptomycin, potentially explaining the natural DAP-

592   sensitivity of *E. faecalis* and why clinical resistance can emerge via regulatory mutations.

References

593   **References**

594   1.   Organisation for Economic Co-operation and Development. Antimicrobial Resistance.

595   Tackling the Burden in the European Union. *Eur Cent Dis Prev Control*. 2020:1-20.

596   https://www.oecd.org/health/health-systems/AMR-Tackling-the-Burden-in-the-EU-OECD-

597   ECDC-Briefing-Note-2019.pdf.

598   2.   Zhen X, Lundborg CS, Sun X, Hu X, Dong H. Economic burden of antibiotic resistance in

599   ESKAPE organisms: a systematic review. *Antimicrob Resist Infect Control*. 2019;8:137.

600   doi:10.1186/s13756-019-0590-7

601   3.   Miller WR, Murray BE, Rice LB, Arias CA. Vancomycin-Resistant Enterococci: Therapeutic

602   Challenges in the 21st Century. *Infect Dis Clin North Am*. 2016;30(2):415-439.

603   doi:10.1016/j.idc.2016.02.006

604   4.   Chiang H-Y, Perencevich EN, Nair R, *et al*. Incidence and Outcomes Associated With

605   Infections Caused by Vancomycin-Resistant Enterococci in the United States: Systematic

606   Literature Review and Meta-Analysis. *Infect Control Hosp Epidemiol*. 2017;38(2):203-215.

607   doi:10.1017/ice.2016.254

608   5.   Said MS, Tirthani E, Lesho E. *Enterococcus Infections*. Rochester General Hospital: StatPearls

609   Publishing, Treasure Island (FL); 2021. http://europepmc.org/abstract/MED/33620836.

610   6.   Arias CA, Murray BE. The rise of the Enterococcus: Beyond vancomycin resistance. *Nat Rev*

611   *Microbiol*. 2012;10(4):266-278. doi:10.1038/nrmicro2761

612   7.   Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-Mediated Resistance to Vancomycin and

613   Teicoplanin in *Enterococcus faecium*. *N Engl J Med*. 1988;319(3):157-161.

614   doi:10.1056/NEJM198807213190307

615   8.   Uttley AHC, George RC, Naidoo J, *et al*. High-level vancomycin-resistant enterococci causing

616   hospital infections. *Epidemiol Infect*. 1989;103(1):173-181. doi:DOI:

617   10.1017/S0950268800030478

618   9.   Levine DP. Vancomycin: A History. *Clin Infect Dis*. 2006;42(Supplement_1):S5-S12.

619   doi:10.1086/491709

620   10. Courvalin P. Vancomycin Resistance in Gram-Positive Cocci. *Clin Infect Dis*.

621   2006;42(Supplement_1):S25-S34. doi:10.1086/491711

622   11. Puchter L, Chaberny IF, Schwab F, Vonberg R-P, Bange F-C, Ebadi E. Economic burden of

623   nosocomial infections caused by vancomycin-resistant enterococci. *Antimicrob Resist Infect*

624   *Control*. 2018;7(1):1. doi:10.1186/s13756-017-0291-z

625   12. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: A Review 4 Years

626   after First Approval. *Pharmacology*. 2008;81(2):79-91. doi:10.1159/000109868

627   13. Munoz-Price LS, Lolans K, Quinn JP. Emergence of Resistance to Daptomycin during

628   Treatment of Vancomycin-Resistant *Enterococcus faecalis* Infection. *Clin Infect Dis*.

629   2005;41(4):565-566. doi:10.1086/432121

630   14. Arias CA, Panesso D, McGrath DM, *et al*. Genetic Basis for In Vivo Daptomycin Resistance

631   in Enterococci. *N Engl J Med*. 2011;365(10):892-900. doi:10.1056/NEJMoa1011138

632   15. Tran T, Panesso D, Mishra Nagendra N, *et al*. Daptomycin-Resistant *Enterococcus faecalis*

633   Diverts the Antibiotic Molecule from the Division Septum and Remodels Cell Membrane

634   Phospholipids. *MBio*. 2013;4(4):e00281-13. doi:10.1128/mBio.00281-13

635   16. Reyes J, Panesso D, Tran TT, *et al*. A *liaR* Deletion Restores Susceptibility to Daptomycin and

636   Antimicrobial Peptides in Multidrug-Resistant *Enterococcus faecalis*. *J Infect Dis*.

637   2015;211(8):1317-1325. doi:10.1093/infdis/jiu602

638   17. Palmer K, Daniel A, Hardy C, Silverman J, Gilmore M. Genetic Basis for Daptomycin

639   Resistance in Enterococci. *Antimicrob Agents Chemother*. 2011;55(7):3345-3356.

640   doi:10.1128/AAC.00207-11

641   18. Tran TT, Miller WR, Shamoo Y, Arias CA. Targeting cell membrane adaptation as a novel

642   antimicrobial strategy. *Curr Opin Microbiol*. 2016;33:91-96.

643   doi:https://doi.org/10.1016/j.mib.2016.07.002

644   19.   Miller C, Kong J, Tran TT, Arias CA, Saxer G, Shamoo Y. Adaptation of *Enterococcus*

645   *faecalis* to daptomycin reveals an ordered progression to resistance. *Antimicrob Agents*

646   *Chemother*. 2013;57(11):5373-5383. doi:10.1128/AAC.01473-13

647   20.   Jordan S, Junker A, Helmann J, Mascher T. Regulation of LiaRS-Dependent Gene Expression

648   in *Bacillus subtilis*: Identification of Inhibitor Proteins, Regulator Binding Sites, and Target

649   Genes of a Conserved Cell Envelope Stress-Sensing Two-Component System. *J Bacteriol*.

650   2006;188(14):5153-5166. doi:10.1128/JB.00310-06

651   21.   Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K. Two-component system

652   VraSR positively modulates the regulation of cell-wall biosynthesis pathway in

653   *Staphylococcus aureus*. *Mol Microbiol*. 2003;49(3):807-821.

654   doi:https://doi.org/10.1046/j.1365-2958.2003.03599.x

655   22.   Martínez B, Zomer AL, Rodríguez A, Kok J, Kuipers OP. Cell envelope stress induced by the

656   bacteriocin Lcn972 is sensed by the lactococcal two-component system CesSR. *Mol*

657   *Microbiol*. 2007;64(2):473-486. doi:https://doi.org/10.1111/j.1365-2958.2007.05668.x

658   23.   Suntharalingam P, Senadheera MD, Mair RW, Levesque CM, Cvitkovitch DG. The LiaFSR

659   system regulates the cell envelope stress response in *Streptococcus mutans*. *J Bacteriol*.

660   2009;191(9):2973-2984. doi:10.1128/JB.01563-08

661   24.   Wolf D, Kalamorz F, Wecke T, *et al*. In-Depth Profiling of the LiaR Response of *Bacillus*

662   *subtilis*. *J Bacteriol*. 2010;192(18):4680-4693. doi:10.1128/JB.00543-10

663   25.   Schrecke K, Jordan S, Mascher T. Stoichiometry and perturbation studies of the LiaFSR

664   system of *Bacillus subtilis*. *Mol Microbiol*. 2013;87(4):769-788.

665   doi:https://doi.org/10.1111/mmi.12130

666   26.   Wolf D, Domínguez-Cuevas P, Daniel R, Mascher T. Cell Envelope Stress Response in Cell

667   Wall-Deficient L-Forms of *Bacillus subtilis*. *Antimicrob Agents Chemother*.

668   2012;56(11):5907-5915. doi:10.1128/AAC.00770-12

669   27. Khan A, Davlieva M, Panesso D, *et al*. Antimicrobial sensing coupled with cell membrane

670   remodeling mediates antibiotic resistance and virulence in *Enterococcus faecalis*. *Proc Natl*

671   *Acad Sci*. 2019;116(52):26925-26932. doi:10.1073/pnas.1916037116

672   28. Comenge Y, Quintiliani R, Li L, *et al*. The CroRS Two-Component Regulatory System Is

673   Required for Intrinsic β-Lactam Resistance in *Enterococcus faecalis*. *J Bacteriol*.

674   2003;185(24):7184-7192. doi:10.1128/JB.185.24.7184-7192.2003

675   29. Winkler ME, Hoch JA. Essentiality, bypass, and targeting of the YycFG (VicRK) two-

676   component regulatory system in gram-positive bacteria. *J Bacteriol*. 2008;190(8):2645-2648.

677   doi:10.1128/JB.01682-07

678   30. Kristich C, Wells C, Dunny G. A eukaryotic-type Ser/Thr kinase in *Enterococcus faecalis*

679   mediates antimicrobial resistance and intestinal persistence. *Proc Natl Acad Sci*.

680   2007;104(9):3508-3513. doi:10.1073/pnas.0608742104

681   31. Kristich C, Little J, Hall C, Hoff J, Low D. Reciprocal Regulation of Cephalosporin Resistance

682   in *Enterococcus faecalis*. *MBio*. 2011;2(6):e00199-11. doi:10.1128/mBio.00199-11

683   32. Iannetta AA, Minton NE, Uitenbroek AA, *et al*. IreK-Mediated, Cell Wall-Protective

684   Phosphorylation in *Enterococcus faecalis*. *J Proteome Res*. 2021;20(11):5131-5144.

685   doi:10.1021/acs.jproteome.1c00635

686   33. Gebhard S, Fang C, Shaaly A, *et al*. Identification and characterization of a bacitracin

687   resistance network in *Enterococcus faecalis*. *Antimicrob Agents Chemother*. 2014.

688   doi:10.1128/AAC.02111-13

689   34. Fritz G, Dintner S, Treichel SN, *et al*. A New Way of Sensing: Need-Based Activation of

690   Antibiotic Resistance by a Flux-Sensing Mechanism. *MBio*. 2015;6(4):e00975-15.

691   doi:10.1128/mBio.00975-15

692   35. Storm DR. Mechanism of Bacitracin Action: A Specific Lipid-Peptide Interaction. *Ann N Y*

693   *Acad Sci*. 1974;235(1):387-398. doi:https://doi.org/10.1111/j.1749-6632.1974.tb43278.x

694   36.   Storm DR, Strominger JL. Binding of bacitracin to cells and protoplasts of Micrococcus

695   lysodeikticus. *J Biol Chem*. 1974;249(6):1823-1827. doi:10.1016/s0021-9258(19)42861-5

696   37.   Dintner S, Heermann R, Fang C, Jung K, Gebhard S. A sensory complex consisting of an

697   ATP-binding cassette transporter and a two-component regulatory system controls bacitracin

698   resistance in *Bacillus subtilis*. *J Biol Chem*. 2014;289(40):27899-27910.

699   doi:10.1074/jbc.M114.596221

700   38.   Koh A, Gibbon MJ, Van der Kamp MW, Pudney CR, Gebhard S. Conformation control of the

701   histidine kinase BceS of *Bacillus subtilis* by its cognate ABC-transporter facilitates need-based

702   activation of antibiotic resistance. *Mol Microbiol*. 2021;115(1):157-174.

703   doi:https://doi.org/10.1111/mmi.14607

704   39.   Kobras C, Piepenbreier H, Emenegger J, Sim A, Fritz G, Gebhard S. BceAB-Type Antibiotic

705   Resistance Transporters Appear To Act by Target Protection of Cell Wall Synthesis.

706   *Antimicrob Agents Chemother*. 2020;64(3):e02241-19. doi:10.1128/AAC.02241-19

707   40.   Ohki R, Giyanto, Tateno K, *et al*. The BceRS two-component regulatory system induces

708   expression of the bacitracin transporter, BceAB, in *Bacillus subtilis*. *Mol Microbiol*.

709   2003;49(4):1135-1144. doi:https://doi.org/10.1046/j.1365-2958.2003.03653.x

710   41.   Prater A, Mehta H, Kosgei A, *et al*. Environment Shapes the Accessible Daptomycin

711   Resistance Mechanisms in *Enterococcus faecium*. *Antimicrob Agents Chemother*.

712   2019;63(10):e00790-19. doi:10.1128/AAC.00790-19

713   42.   Prater A, Mehta H, Beabout K, *et al*. Daptomycin Resistance in *Enterococcus faecium* Can Be

714   Delayed by Disruption of the LiaFSR Stress Response Pathway. *Antimicrob Agents*

715   *Chemother*. 2021;65(4):e01317-20. doi:10.1128/AAC.01317-20

716   43.   Mascher T, Margulis NG, Wang T, Ye RW, Helmann JD. Cell wall stress responses in

717   *Bacillus subtilis*: the regulatory network of the bacitracin stimulon. *Mol Microbiol*.

718   2003;50(5):1591-1604. doi:https://doi.org/10.1046/j.1365-2958.2003.03786.x

719   44.   Rietkötter E, Hoyer D, Mascher T. Bacitracin sensing in *Bacillus subtilis*. *Mol Microbiol*.

720   2008;68(3):768-785. doi:https://doi.org/10.1111/j.1365-2958.2008.06194.x

721   45.   Radeck J, Gebhard S, Orchard PS, *et al*. Anatomy of the bacitracin resistance network in

722   *Bacillus subtilis*. *Mol Microbiol*. 2016;100(4):607-620. doi:10.1111/mmi.13336

723   46.   Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Götz F. Inactivation of the *dlt* Operon in

724   *Staphylococcus aureus* Confers Sensitivity to Defensins, Protegrins, and Other Antimicrobial

725   Peptides. *J Biol Chem*. 1999;274(13):8405-8410. doi:10.1074/jbc.274.13.8405

726   47.   Tran T, Munita J, Arias C. Mechanisms of drug resistance: daptomycin resistance. *Ann N Y*

727   *Acad Sci*. 2015;1354(1):32-53. doi:https://doi.org/10.1111/nyas.12948

728   48.   Wecke T, Zühlke D, Mäder U, *et al*. Daptomycin versus Friulimicin B: In-Depth Profiling of

729   *Bacillus subtilis* Cell Envelope Stress Responses. *Antimicrob Agents Chemother*.

730   2009;53(4):1619-1623. doi:10.1128/AAC.01046-08

731   49.   Hachmann A., Angert E, Helmann J. Genetic Analysis of Factors Affecting Susceptibility of

732   *Bacillus subtilis* to Daptomycin. *Antimicrob Agents Chemother*. 2009;53(4):1598-1609.

733   doi:10.1128/AAC.01329-08

734   50.   Grein F, Müller A, Scherer KM, *et al*. Ca^{2+}-Daptomycin targets cell wall biosynthesis by

735   forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids.

736   *Nat Commun*. 2020;11(1):1455. doi:10.1038/s41467-020-15257-1

737   51.   Tendolkar PM, Baghdayan AS, Shankar N. Pathogenic enterococci: new developments in the

738   21st century. *Cell Mol Life Sci C*. 2003;60(12):2622-2636. doi:10.1007/s00018-003-3138-0

739   52.   Eckburg P, Bik E, Charles B, *et al*. Diversity of the Human Intestinal Microbial Flora. *Science*

740   *(80-)*. 2005;308(5728):1635-1638. doi:10.1126/science.1110591

741   53.   Sghir A, Gramet G, Suau A, Rochet V, Pochart P, Dore J. Quantification of Bacterial Groups

742   within Human Fecal Flora by Oligonucleotide Probe Hybridization. *Appl Environ Microbiol*.

743   2000;66(5):2263-2266. doi:10.1128/AEM.66.5.2263-2266.2000

744 54.   Lorian V. Colonization resistance. *Antimicrob Agents Chemother*. 1994;38(7):1693.

745   doi:10.1128/AAC.38.7.1693

746 55.   Banerjee S, Hansen JN. Structure and expression of a gene encoding the precursor of subtilin,

747   a small protein antibiotic. *J Biol Chem*. 1988;263(19):9508-9514.

748   doi:https://doi.org/10.1016/S0021-9258(19)76571-5

749 56.   Johnson B, Anker H, Meleney F. Bacitracin: A New Antibiotic Produced by a Member of the

750   *B. subtilis* Group. *Science (80-)*. 1945;102(2650):376-377. doi:10.1126/science.102.2650.376

751 57.   Kuipers OP, de Ruyter PGGA, Kleerebezem M, de Vos WM. Quorum sensing-controlled gene

752   expression in lactic acid bacteria. *J Biotechnol*. 1998;64(1):15-21.

753   doi:https://doi.org/10.1016/S0168-1656(98)00100-X

754 58.   Aldarhami A, Felek A, Sharma V, Upton M. Purification and characterization of nisin P

755   produced by a strain of *Streptococcus gallolyticus*. *J Med Microbiol*. 2020;69(4):605-616.

756   doi:https://doi.org/10.1099/jmm.0.001170

757 59.   Storm DR, Strominger JL. Complex Formation between Bacitracin Peptides and Isoprenyl

758   Pyrophosphates. *J Biol Chem*. 1973;248(11):3940-3945. doi:10.1016/s0021-9258(19)43823-4

759 60.   Economou N, Cocklin S, Loll P. High-resolution crystal structure reveals molecular details of

760   target recognition by bacitracin. *Proc Natl Acad Sci*. 2013;110(35):14207-14212.

761   doi:10.1073/pnas.1308268110

762 61.   Cudic P, Kranz J, Behenna D, *et al*. Complexation of peptidoglycan intermediates by the

763   lipoglycodepsipeptide antibiotic ramoplanin: Minimal structural requirements for

764   intermolecular complexation and fibril formation. *Proc Natl Acad Sci*. 2002;99(11):7384-

765   7389. doi:10.1073/pnas.102192099

766 62.   Staroń A, Finkeisen DE, Mascher T. Peptide antibiotic sensing and detoxification modules of

767   *Bacillus subtilis*. *Antimicrob Agents Chemother*. 2011;55(2):515-525.

768   doi:10.1128/AAC.00352-10

769   63.   Gebhard S, Mascher T. Antimicrobial peptide sensing and detoxification modules: Unravelling

770   the regulatory circuitry of *Staphylococcus aureus*. *Mol Microbiol*. 2011;81(3):581-587.

771   doi:10.1111/j.1365-2958.2011.07747.x

772   64.   Wu S, Lin K, Liu Y, Zhang H, Lei L. Two-component signaling pathways modulate drug

773   resistance of *Staphylococcus aureus* (Review). *Biomed Rep*. 2020;13(2):5.

774   doi:10.3892/br.2020.1312

775   65.   Arii K, Kawada-Matsuo M, Oogai Y, Noguchi K, Komatsuzawa H. Single mutations in BraRS

776   confer high resistance against nisin A in *Staphylococcus aureus*. *Microbiologyopen*.

777   2019;8(11):e791. doi:https://doi.org/10.1002/mbo3.791

778   66.   Meehl M, Herbert S, Götz F, Cheun A. Interaction of the GraRS Two-Component System with

779   the VraFG ABC Transporter To Support Vancomycin-Intermediate Resistance in

780   *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2007;51(8):2679-2689.

781   doi:10.1128/AAC.00209-07

782   67.   Ledger EVK, Mesnage S, Edwards AM. Human serum triggers antibiotic tolerance in

783   *Staphylococcus aureus*. *Nat Commun*. 2022;13(1):2041. doi:10.1038/s41467-022-29717-3

784   68.   Cheung AL, Bayer AS, Yeaman MR, *et al*. Site-specific mutation of the sensor kinase *graS* in

785   *Staphylococcus aureus* alters the adaptive response to distinct cationic antimicrobial peptides.

786   *Infect Immun*. 2014;82(12):5336-5345. doi:10.1128/IAI.02480-14

787   69.   Kraus D, Herbert S, Kristian SA, *et al*. The GraRS regulatory system controls *Staphylococcus*

788   *aureus* susceptibility to antimicrobial host defenses. *BMC Microbiol*. 2008;8(1):85.

789   doi:10.1186/1471-2180-8-85

790   70.   Bayer AS, Mishra NN, Cheung AL, Rubio A, Yang S-J. Dysregulation of *mprF* and *dltABCD*

791   expression among daptomycin-non-susceptible MRSA clinical isolates. *J Antimicrob*

792   *Chemother*. 2016;71(8):2100-2104. doi:10.1093/jac/dkw142

793 71. Yang S, Kreiswirth BN, Sakoulas G, *et al*. Enhanced Expression of *dltABCD* Is Associated

794   with the Development of Daptomycin Nonsusceptibility in a Clinical Endocarditis Isolate of

795   *Staphylococcus aureus*. *J Infect Dis*. 2009;200(12):1916-1920. doi:10.1086/648473

796 72. Cafiso V, Bertuccio T, Purrello S, *et al*. *dltA* overexpression: A strain-independent keystone of

797   daptomycin resistance in methicillin-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents*.

798   2014;43(1):26-31. doi:https://doi.org/10.1016/j.ijantimicag.2013.10.001

799 73. Mishra NN, Bayer AS, Weidenmaier C, *et al*. Phenotypic and Genotypic Characterization of

800   Daptomycin-Resistant Methicillin-Resistant *Staphylococcus aureus* Strains: Relative Roles of

801   *mprF* and *dlt* Operons. *PLoS One*. 2014;9(9):e107426.

802   https://doi.org/10.1371/journal.pone.0107426.

803 74. Bertsche U, Weidenmaier C, Kuehner D, *et al*. Correlation of Daptomycin Resistance in a

804   Clinical *Staphylococcus aureus* Strain with Increased Cell Wall Teichoic Acid Production and

805   d-Alanylation. *Antimicrob Agents Chemother*. 2011;55(8):3922-3928.

806   doi:10.1128/AAC.01226-10

807 75. Turnidge J, Kahlmeter G, Cantón R, MacGowan A, Giske CG. Daptomycin in the treatment of

808   enterococcal bloodstream infections and endocarditis: a EUCAST position paper. *Clin*

809   *Microbiol Infect*. 2020;26(8):1039-1043. doi:10.1016/j.cmi.2020.04.027

810 76. Cruz-Rodz AL, Gilmore MS. High efficiency introduction of plasmid DNA into glycine

811   treated *Enterococcus faecalis* by electroporation. *Mol Gen Genet MGG*. 1990;224(1):152-154.

812   doi:10.1007/BF00259462

813 77. Hanahan D, Glover DM. DNA cloning: a practical approach. *DNA cloning a Pract approach*.

814   1985;1:109-135.

815 78. Poyart C, Trieu-Cuot P. A broad-host-range mobilizable shuttle vector for the construction of

816   transcriptional fusions to β-galactosidase in Gram-positive bacteria. *FEMS Microbiol Lett*.

817   1997;156(2):193-198. doi:10.1111/j.1574-6968.1997.tb12726.x

818   79.   Thurlow L, Chittezham TV, Hancock L. Capsular Polysaccharide Production in *Enterococcus*

819   *faecalis* and Contribution of CpsF to Capsule Serospecificity. *J Bacteriol*. 2009;191(20):6203-

820   6210. doi:10.1128/JB.00592-09

821   80.   Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap

822   extension using the polymerase chain reaction. *Gene*. 1989;77(1):51-59.

823   doi:https://doi.org/10.1016/0378-1119(89)90358-2

824   81.   Kristich CJ, Chandler JR, Dunny GM. Development of a host-genotype-independent

825   counterselectable marker and a high-frequency conjugative delivery system and their use in

826   genetic analysis of *Enterococcus faecalis*. *Plasmid*. 2007;57(2):131-144.

827   doi:https://doi.org/10.1016/j.plasmid.2006.08.003

828   82.   Gebhard S, Tran SL, Cook GM. The Phn system of Mycobacterium smegmatis: a second high-

829   affinity ABC-transporter for phosphate. *Microbiology*. 2006;152(11):3453-3465.

830   doi:https://doi.org/10.1099/mic.0.29201-0

831   83.   Piepenbreier H, Sim A, Kobras CM, *et al*. From Modules to Networks: a Systems-Level

832   Analysis of the Bacitracin Stress Response in *Bacillus subtilis*. *mSystems*. 2020;5(1):e00687-

833   19. doi:10.1128/mSystems.00687-19

834   84.   Allen D. Transcriptional regulation of the *dlt* operon in *Enterococcus faecalis* and further

835   characterization of a *dltA* mutant. 2008.

836

Supplementary Material

838   **Table S1.** Vectors, plasmids and strains used in this study.

839   **Table S2.** Primers used in this study.

840   **Table S3.** Parameter values used in the mathematical model.

841   **Table S4.** Experimental numerical data for Figures 1, 3 and 4.

842   **File S1.** Mathematical model file for the application *Mathematica*